It’s a straight line up. The goods and services deficit kicked off January by rising a record 34% over December. Importers are front running tariffs and getting in their orders before everything changes, likely at some point after April 1.
It took nine months to rescue two astronauts stuck on the International Space Station this weekend, yet somehow President Trump is expected to rewrite global trade rules between the U.S. and 166 World Trade Organization-member countries in less than two months.
Strong federal investment in the National Science Foundation and National Institutes of Health is vital for American innovation, economic growth, and national security.
For years, the de minimis loophole has flooded the U.S. with uninspected, untaxed, and often dangerous goods—from counterfeit products to fentanyl precursors fueling America’s opioid crisis.
Investors’ panic is misguided—history proves President Trump’s tariffs boost investment, jobs, and long-term American prosperity.
Tariffs are an effective tool for boosting domestic production. They stimulate critical domestic investment and increase U.S. manufacturing capacity. It’s past time to abandon the outdated dogma of unregulated free trade — and start focusing on rebuilding American industry to create jobs and ensure long-term economic resilience.
Nine different companies joined members of the House Select Committee on China at a press conference on Wednesday to talk about their battles with “China trade cheats” that have cost them a fortune. Most of them closed factories, or rolled back investment. Despite tariffs and anti-dumping (AD/CVD) trade case victories, the battle continues.
CPA’s report demonstrates that previous tariff exemptions and exclusions significantly weakened the effectiveness of the original tariffs imposed in 2018.
In a House Oversight subcommittee hearing on Feb. 26, the Inflation Reduction Act (IRA) was hit with the usual swipes from detractors, with some calling it the “green scam”, but China’s solar company benefits were never mentioned.
In 2024, China and India accounted for 57.6% of total U.S. pharmaceutical imports by weight, highlighting the potential risks associated with such reliance. Growing U.S. dependence on China and India for widely-used generic pharmaceutical products creates serious risks to national security and patient safety when drugs are in short supply, or ineffective.
